Hamostaseologie最新文献_第4页

Management of Recurrent Venous Thromboembolism in Severe Immune Thrombocytopenia: A Case Report and a Review of the Literature. 严重免疫性血小板减少症复发性静脉血栓栓塞的治疗：一例报告和文献复习。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-10-01 Epub Date: 2023-10-31 DOI: 10.1055/a-2159-8722

Mathias Haargaard Nielsen, Mustafa Vakur Bor

引用次数: 0

Bleeding Risk in Patients with Cancer. 癌症患者的出血风险。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-09-03 DOI: 10.1055/a-2347-6507

Cornelia Englisch, Nikola Vladic, Cihan Ay

{"title":"Bleeding Risk in Patients with Cancer.","authors":"Cornelia Englisch, Nikola Vladic, Cihan Ay","doi":"10.1055/a-2347-6507","DOIUrl":"https://doi.org/10.1055/a-2347-6507","url":null,"abstract":"The hemostatic system and cancer display a tight interconnection, and hemostatic imbalance frequently occurs in patients with cancer. While extensive knowledge about thrombotic risk has been generated, less is known about bleeding risk and associated risk factors. However, bleeding risk is of high significance as patients with cancer frequently receive therapeutic anticoagulation for various indications and/or are candidates for primary thromboprophylaxis. The risk of bleeding in patients with cancer is variable and difficult to assess in clinical practice. Certain clinical settings such as hospitalization, specific underlying risk factors (e.g., tumor type), and medications (e.g., anticoagulation) can contribute to the individual bleeding risk of a patient with cancer. In addition, some dynamic factors such as platelet count or kidney function have an impact. Particularly, data on baseline risk of bleeding are lacking to allow for risk assessment in cancer patients without anticoagulation. In contrast, risk assessment models for the prediction of bleeding events in cancer patients receiving anticoagulation have been developed; however, these have yet to be validated. The recognition of the importance of bleeding risk in cancer patients is growing, leading to an increasing number of studies investigating and reporting bleeding complications. As study designs and reporting of bleeding events vary, it is challenging to offer a clear synthesis of evidence. In this narrative review, we provide an overview of currently available data about incidence, risk factors, and clinical impact of bleeding events in patients with cancer, and critically review risk assessment models for bleeding in cancer patients during anticoagulant therapy.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chronic Venous Disease: Pathophysiological Aspects, Risk Factors, and Diagnosis. 慢性静脉疾病：病理生理学方面、风险因素和诊断。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-07-11 DOI: 10.1055/a-2315-6206

Philip Kienzl, Julia Deinsberger, Benedikt Weber

引用次数: 0

Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics. 儿科使用血小板生成素受体激动剂的最新情况。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-06-26 DOI: 10.1055/a-2247-4209

Jennifer Gebetsberger, Werner Streif, Christof Dame

{"title":"Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics.","authors":"Jennifer Gebetsberger, Werner Streif, Christof Dame","doi":"10.1055/a-2247-4209","DOIUrl":"10.1055/a-2247-4209","url":null,"abstract":"This review summarizes the rationale and current data on the use of thrombopoietin receptor agonists (TPO-RAs) for treating severe thrombocytopenia in infants, children, and adolescents. It focuses on substances that have been approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for pediatric patients. Romiplostim and eltrombopag are already established as second-line treatment for persistent or chronic immune thrombocytopenia (ITP). As in adults, TPO-RAs are currently also evaluated in severe aplastic anemia (SAA), chemotherapy-induced thrombocytopenia (CIT), myelodysplastic syndromes (MDS), and poor engraftment after hematopoietic stem cell transplantation in pediatric and adolescent patients. Moreover, studies on the implication of TPO-RA in treating rare inherited thrombocytopenias, such as Wiskott-Aldrich syndrome (WAS), congenital amegakaryocytic thrombocytopenia (CAMT), or MYH9-associated thrombocytopenia, deserve future attention. Current developments include testing of avatrombopag and lusutrombopag that are approved for the treatment of thrombocytopenia associated with chronic liver disease (CLD) in adult patients. In pediatric and adolescent medicine, we expect in the near future a broader use of TPO-RAs as first-line treatment in primary ITP, thereby considering immunomodulatory effects that increase the rate of sustained remission off-treatment, and a selective use in rare inherited thrombocytopenias based on current clinical trials.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"316-325"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blutspende auch ohne Arztanwesenheit und aktueller Stand des Apothekenreform-Gesetzes (ApoRG). 无医生在场情况下的献血以及《药房改革法》（ApoRG）的现状。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-08-16 DOI: 10.1055/a-2288-0540

Jürgen Koscielny, Günther Kappert, Christoph Sucker

引用次数: 0

Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion. 原因不明的出血性疾病：排除性诊断。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-02-27 DOI: 10.1055/a-2263-5706

Dino Mehic, Johanna Gebhart, Ingrid Pabinger

{"title":"Bleeding Disorder of Unknown Cause: A Diagnosis of Exclusion.","authors":"Dino Mehic, Johanna Gebhart, Ingrid Pabinger","doi":"10.1055/a-2263-5706","DOIUrl":"10.1055/a-2263-5706","url":null,"abstract":"Patients with an unexplained mild to moderate bleeding tendency are diagnosed with bleeding disorder of unknown cause (BDUC), a classification reached after ruling out other mild to moderate bleeding disorders (MBD) including von Willebrand disease (VWD), platelet function defects (PFDs), coagulation factor deficiencies (CFDs), and non-hemostatic causes for bleeding. This review outlines our diagnostic approach to BDUC, a diagnosis of exclusion, drawing on current guidelines and insights from the Vienna Bleeding Biobank (VIBB). According to guidelines, we diagnose VWD based on VWF antigen and/or activity levels ≤50 IU/dL, with repeated VWF testing if VWF levels are <80 IU/dL. This has been introduced in our clinical routine after our findings of diagnostically relevant fluctuations of VWF levels in a high proportion of MBD patients. PFDs are identified through repeated abnormalities in light transmission aggregometry (LTA), flow cytometric mepacrine fluorescence, and glycoprotein expression analysis. Nevertheless, we experience diagnostic challenges with regard to reproducibility and unspecific alterations of LTA. For factor (F) VIII and FIX deficiency, a cutoff of 50% is utilized to ensure detection of mild hemophilia A or B. We apply established cutoffs for other rare CFD being aware that these do not clearly reflect the causal role of the bleeding tendency. Investigations into very rare bleeding disorders due to hyperfibrinolysis or increase in natural anticoagulants are limited to cases with a notable family history or distinct bleeding phenotypes considering cost-effectiveness. While the pathogenesis of BDUC remains unknown, further explorations of this intriguing area may reveal new mechanisms and therapeutic targets.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"287-297"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139984612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clot-Wave-Analyse könnte individualisierte Therapie bei Hämophilie A verbessern. 血块波分析可改善血友病 A 的个体化治疗。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-08-16 DOI: 10.1055/s-0044-1789285

引用次数: 0

Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment. 脾静脉血栓：抗凝治疗的最新进展。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-02-14 DOI: 10.1055/a-2232-5480

Scott Custo, Emma Tabone, Alexia Aquilina, Alex Gatt, Nicoletta Riva

{"title":"Splanchnic Vein Thrombosis: The State-of-the-Art on Anticoagulant Treatment.","authors":"Scott Custo, Emma Tabone, Alexia Aquilina, Alex Gatt, Nicoletta Riva","doi":"10.1055/a-2232-5480","DOIUrl":"10.1055/a-2232-5480","url":null,"abstract":"Splanchnic vein thrombosis (SVT) is a rare type of venous thromboembolism occurring within the splanchnic venous system. Portal vein thrombosis is the most common presentation, while Budd-Chiari syndrome is the least common. Liver cirrhosis and abdominal solid cancer are the main local risk factors for SVT, whereas myeloproliferative neoplasms are the predominant systemic risk factors. Signs and symptoms of SVT are nonspecific and include abdominal pain, gastrointestinal bleeding, and ascites. Asymptomatic SVT is not uncommon, and the majority would be detected incidentally on routine abdominal imaging performed for the follow-up of liver diseases and tumors. The management of SVT aims to prevent thrombus progression, promote vessel recanalization, and prevent recurrent venous thromboembolism. Anticoagulation should be started early in order to increase the chances of vessel recanalization and reduce the risk of portal hypertension-related complications. Direct oral anticoagulants have been included in recent guidelines, as alternatives to vitamin K antagonists, after clinical stability has been reached; however, caution is required in patients with liver or kidney dysfunction. Treatment duration is based on the presence (or absence) and type (transient vs. permanent) of risk factors. This narrative review aims to summarize the latest evidence on SVT, with a particular focus on the anticoagulant treatment in special categories of patients (e.g., liver cirrhosis, solid cancer, myeloproliferative neoplasms, pancreatitis, incidentally detected SVT, Budd-Chiari syndrome, and chronic SVT).","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"242-254"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139736827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rivaroxaban ist bei Malignom-assoziierten Thrombembolien nicht unterlegen. 利伐沙班治疗恶性肿瘤相关血栓栓塞症的效果并不差。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-08-16 DOI: 10.1055/s-0044-1789284

引用次数: 0

Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology. 心脏肿瘤学：医学的一门新学科及其与血液学的相关性。

IF 2.7 4区医学

Hamostaseologie Pub Date : 2024-08-01 Epub Date: 2024-05-09 DOI: 10.1055/a-2284-5855

Andreas Spannbauer, Jutta Bergler-Klein

{"title":"Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology.","authors":"Andreas Spannbauer, Jutta Bergler-Klein","doi":"10.1055/a-2284-5855","DOIUrl":"10.1055/a-2284-5855","url":null,"abstract":"Cardio-oncology, a burgeoning subspecialty, addresses the complex interplay between cardiology and oncology, particularly in light of increased cardiovascular (CV) disease mortality in cancer patients. This review provides a comprehensive overview of cardio-oncology with a focus on the therapies used in hematological malignancies. We explore the bidirectional relationship between heart failure and cancer, emphasizing the need for collaborative care. The review discusses risk stratification, highlighting the importance of baseline CV risk assessment and personalized surveillance regimens. Primary and secondary prevention strategies, including pharmacological interventions, are outlined. The review also delves into the cardiotoxicity associated with hematological cancer therapies, focusing on anthracyclines, Bruton kinase inhibitors, BCR-ABL tyrosine kinase inhibitors, CAR-T cell therapy, immune checkpoint inhibitors, multiple myeloma treatments, and hematopoietic stem cell transplantation. We then highlight the high risk of venous and arterial thromboembolisms in cancer patients and the challenges of anticoagulation management in cardio-oncology. Finally, the review touches on the importance of long-term follow-up and appropriate screening in cancer survivors at high risk of CV morbidity and mortality, based on their CV risk profile and the type and dose of cardiotoxic therapies they received such as anthracyclines or high radiation doses.","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"255-267"},"PeriodicalIF":2.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140900423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0